SCHEMBL21554529

SCHEMBL21554529

CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCN(C(C)(C)C)CC4)cn3)nc2n1C1CCCC1

nearest known ligand 0.80

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 17/20 0.80
CDK1 P06493 5/20 0.80
CDK2 P24941 3/20 0.80
CCND3 P30281 3/20 0.79
GAK O14976 1/20 0.79
CCNT1 O60563 1/20 0.79
CCNA2 P20248 1/20 0.79
FECH P22830 1/20 0.79
CCND1 P24385 1/20 0.79
CDK9 P50750 1/20 0.79
CDK6 Q00534 1/20 0.79
CDK16 Q00536 1/20 0.79
MAP3K1 Q13233 1/20 0.79
CAMK2G Q13555 1/20 0.79
CAMK2D Q13557 1/20 0.79
Q6ZSR9 Q6ZSR9 1/20 0.79
PRKD2 Q9BZL6 1/20 0.79
SIK2 Q9H0K1 1/20 0.79
HDAC1 Q13547 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22600074 0.94 CDK4 (0.78) CDK4CDK1CDK2CCND3GAK
SCHEMBL21036418 0.91 CDK4 (0.85) CDK4CDK1CDK2CCND3GAK
SCHEMBL302331 0.91 CDK4 (0.89) CDK4CDK1CDK2CCND3GAK
SCHEMBL30176525 0.91 CDK4 (0.89) CDK4CDK1CDK2CCND3GAK
SCHEMBL21227657 0.91 CDK4 (0.86) CDK4CDK1CDK2CCND3GAK
SCHEMBL19986419 0.90 CDK4 (0.82) CDK4CDK1CDK2CCND3GAK
SCHEMBL28021325 0.90 CDK4 (0.74) CDK4CDK1CDK2CCND3GAK
SCHEMBL22616331 0.90 CDK4 (0.74) CDK4CDK1CDK2CCND3GAK
SCHEMBL2684165 0.89 CDK4 (0.81) CDK4CDK1CDK2CCND3GAK
SCHEMBL1999434 0.89 CDK4 (0.81) CDK4CDK1CDK2CCND3GAK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11541051-B2 Compositions and methods for treating CDK4/6-mediated cancer ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-01-03 US disclosed
US-20210338670-A1 NON-INVASIVE PET IMAGING OF CDK4/6 ACTIVATION IN CANCER NEW YORK UNIVERSITY 2021-11-04 US disclosed
US-11040106-B2 Conjugates of kinase inhibitors and cyanine dyes Small Molecule PPI Mimics LLC (US) 2021-06-22 US disclosed
US-20200339572-A1 NOVEL SELECTIVE CDK4/6 INHIBITOR AND PREPARATION THEREOF WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) 2020-10-29 US disclosed
US-20190343958-A1 CONJUGATES OF KINASE INHIBITORS AND CYANINE DYES UNITED STATES GOVERNMENT 2019-11-14 US disclosed
US-20190336503-A1 COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2019-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210338670-A1 NON-INVASIVE PET IMAGING OF CDK4/6 ACTIVATION IN CANCER CDK4, CDK6, CDKL4 CDK4 1/4885CDK1 9/4885CDK2 7/4885
US-11040106-B2 Conjugates of kinase inhibitors and cyanine dyes ABL1, MAP3K20, MAP4K2 CDK4 324/4885CDK1 105/4885CDK2 108/4885
US-20190336503-A1 COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER CDK4, CDK6, CDK2 CDK4 1/4885CDK1 11/4885CDK2 3/4885
US-20190343958-A1 CONJUGATES OF KINASE INHIBITORS AND CYANINE DYES ABL1, MAP3K20, MAP4K2 CDK4 324/4885CDK1 105/4885CDK2 108/4885
US-20200339572-A1 NOVEL SELECTIVE CDK4/6 INHIBITOR AND PREPARATION THEREOF CDK4, CDK6, CCNI CDK4 1/4885CDK1 7/4885CDK2 12/4885
US-11541051-B2 Compositions and methods for treating CDK4/6-mediated cancer CDK4, CDK6, CDK2 CDK4 1/4885CDK1 11/4885CDK2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.